Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure

Sevil Korkmaz-Icöz, T. Radovits, G. Szabó

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Phosphodiesterase type 5 (PDE5) selectively hydrolyses the second messenger cGMP into 5′-GMP, thereby regulating its intracellular concentrations. Dysregulation of the cGMP-dependent pathway plays a significant role in various cardiovascular diseases. Therefore, its modulation by drugs, such as PDE5 inhibitors, may represent an effective therapeutic approach. There are currently four PDE5 inhibitors available for the treatment of erectile dysfunction: sildenafil, vardenafil, tadalafil and avanafil. Sildenafil and tadalafil have also received Food and Drug Administration approval for the treatment of pulmonary arterial hypertension. This review summarizes the pharmacological aspects and clinical potential of PDE5 inhibition for the treatment of myocardial ischaemia/reperfusion injury and heart failure. Linked Articles: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.

Original languageEnglish
Pages (from-to)223-231
Number of pages9
JournalBritish Journal of Pharmacology
Volume175
Issue number2
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Type 5 Cyclic Nucleotide Phosphodiesterases
Myocardial Reperfusion Injury
Phosphodiesterase 5 Inhibitors
Reperfusion Injury
Myocardial Ischemia
Heart Failure
Drug Repositioning
Guanosine Monophosphate
Drug Approval
Second Messenger Systems
Erectile Dysfunction
United States Food and Drug Administration
Pulmonary Hypertension
Cardiovascular Diseases
Pharmacology
Therapeutics
Pharmaceutical Preparations
Tadalafil
Sildenafil Citrate
Inhibition (Psychology)

ASJC Scopus subject areas

  • Pharmacology

Cite this

Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. / Korkmaz-Icöz, Sevil; Radovits, T.; Szabó, G.

In: British Journal of Pharmacology, Vol. 175, No. 2, 01.01.2018, p. 223-231.

Research output: Contribution to journalReview article

@article{cb339ccc32c54419af8d5fae2dab4182,
title = "Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure",
abstract = "Phosphodiesterase type 5 (PDE5) selectively hydrolyses the second messenger cGMP into 5′-GMP, thereby regulating its intracellular concentrations. Dysregulation of the cGMP-dependent pathway plays a significant role in various cardiovascular diseases. Therefore, its modulation by drugs, such as PDE5 inhibitors, may represent an effective therapeutic approach. There are currently four PDE5 inhibitors available for the treatment of erectile dysfunction: sildenafil, vardenafil, tadalafil and avanafil. Sildenafil and tadalafil have also received Food and Drug Administration approval for the treatment of pulmonary arterial hypertension. This review summarizes the pharmacological aspects and clinical potential of PDE5 inhibition for the treatment of myocardial ischaemia/reperfusion injury and heart failure. Linked Articles: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.",
author = "Sevil Korkmaz-Ic{\"o}z and T. Radovits and G. Szab{\'o}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/bph.13749",
language = "English",
volume = "175",
pages = "223--231",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure

AU - Korkmaz-Icöz, Sevil

AU - Radovits, T.

AU - Szabó, G.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Phosphodiesterase type 5 (PDE5) selectively hydrolyses the second messenger cGMP into 5′-GMP, thereby regulating its intracellular concentrations. Dysregulation of the cGMP-dependent pathway plays a significant role in various cardiovascular diseases. Therefore, its modulation by drugs, such as PDE5 inhibitors, may represent an effective therapeutic approach. There are currently four PDE5 inhibitors available for the treatment of erectile dysfunction: sildenafil, vardenafil, tadalafil and avanafil. Sildenafil and tadalafil have also received Food and Drug Administration approval for the treatment of pulmonary arterial hypertension. This review summarizes the pharmacological aspects and clinical potential of PDE5 inhibition for the treatment of myocardial ischaemia/reperfusion injury and heart failure. Linked Articles: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.

AB - Phosphodiesterase type 5 (PDE5) selectively hydrolyses the second messenger cGMP into 5′-GMP, thereby regulating its intracellular concentrations. Dysregulation of the cGMP-dependent pathway plays a significant role in various cardiovascular diseases. Therefore, its modulation by drugs, such as PDE5 inhibitors, may represent an effective therapeutic approach. There are currently four PDE5 inhibitors available for the treatment of erectile dysfunction: sildenafil, vardenafil, tadalafil and avanafil. Sildenafil and tadalafil have also received Food and Drug Administration approval for the treatment of pulmonary arterial hypertension. This review summarizes the pharmacological aspects and clinical potential of PDE5 inhibition for the treatment of myocardial ischaemia/reperfusion injury and heart failure. Linked Articles: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.

UR - http://www.scopus.com/inward/record.url?scp=85016618137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016618137&partnerID=8YFLogxK

U2 - 10.1111/bph.13749

DO - 10.1111/bph.13749

M3 - Review article

C2 - 28213937

AN - SCOPUS:85016618137

VL - 175

SP - 223

EP - 231

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 2

ER -